201 related articles for article (PubMed ID: 18948744)
1. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.
Kreijtz JH; Osterhaus AD; Rimmelzwaan GF
Hum Vaccin; 2009 Mar; 5(3):126-35. PubMed ID: 18948744
[TBL] [Abstract][Full Text] [Related]
2. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
3. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G
Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753
[TBL] [Abstract][Full Text] [Related]
4. Current status and progress of prepandemic and pandemic influenza vaccine development.
Leroux-Roels I; Leroux-Roels G
Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
[TBL] [Abstract][Full Text] [Related]
5. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
6. Influenza A (H5N1) pandemic prototype vaccine Fluval.
Vajo Z
Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
[TBL] [Abstract][Full Text] [Related]
7. Adjuvants for pandemic influenza vaccines.
Atmar RL; Keitel WA
Curr Top Microbiol Immunol; 2009; 333():323-44. PubMed ID: 19768413
[TBL] [Abstract][Full Text] [Related]
8. Vaccines for pandemic influenza.
Luke CJ; Subbarao K
Emerg Infect Dis; 2006 Jan; 12(1):66-72. PubMed ID: 16494720
[TBL] [Abstract][Full Text] [Related]
9. NEW technologies for meeting the global demand for pandemic influenza vaccines.
Fedson DS
Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
[TBL] [Abstract][Full Text] [Related]
10. Vaccines for seasonal and pandemic influenza.
Nichol KL; Treanor JJ
J Infect Dis; 2006 Nov; 194 Suppl 2():S111-8. PubMed ID: 17163383
[TBL] [Abstract][Full Text] [Related]
11. Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.
Zheng D; Yi Y; Chen Z
Viruses; 2012 Dec; 4(12):3589-605. PubMed ID: 23223214
[TBL] [Abstract][Full Text] [Related]
12. Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009.
Hayden FG; Howard WA; Palkonyay L; Kieny MP
Vaccine; 2009 Jun; 27(31):4079-89. PubMed ID: 19406184
[TBL] [Abstract][Full Text] [Related]
13. Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
Keitel WA; Atmar RL
Curr Opin Pharmacol; 2007 Oct; 7(5):484-90. PubMed ID: 17644429
[TBL] [Abstract][Full Text] [Related]
14. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
Carter NJ; Plosker GL
BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
[TBL] [Abstract][Full Text] [Related]
15. [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations].
de Jong JC; Osterhaus AD
Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2113-5. PubMed ID: 18856026
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
17. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
18. Emulsion-based adjuvants for influenza vaccines.
Vogel FR; Caillet C; Kusters IC; Haensler J
Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
[TBL] [Abstract][Full Text] [Related]
20. Reference viruses for seasonal and pandemic influenza vaccine preparation.
Wood JS; Robertson JS
Influenza Other Respir Viruses; 2007 Jan; 1(1):5-9. PubMed ID: 19459278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
